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Abstract
Obesity is associated with type 2 diabetes, insulin resistance and low grade inﬂammation. The gut microbiota is now considered as one
of the most important environmental factors impacting on host physiology and metabolism. We have recently pointed out the role of
this ‘organ’ on the onset of insulin resistance and the low grade inﬂammatory tone characterizing obesity. Among the mechanisms, we
have introduced the novel concept of metabolic endotoxaemia as factor triggering low grade inﬂammation and associated disorders.
More recently, two novel mechanisms involved in the development of gut permeability and adipose tissue plasticity have been identiﬁed.
Speciﬁc attention has been paid to the role of the glucagon-like peptide 2 and the endocannabinoid system. This review brieﬂy discusses
the role of prebiotics as a key tool to modulate the gut microbiota, the gut barrier function, inﬂammation and the insulin resistance
associated with obesity.
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Introduction
Nowadays, obesity is associated with a cluster of metabolic
disorders including glucose homeostasis disorders (i.e. glu-
cose intolerance, insulin resistance, type 2 diabetes) and car-
diovascular diseases or risk factors (hypertension,
dyslipidaemia, ﬁbrinolysis disorders, atherosclerosis) [1].
Over the past decade, the scientiﬁc community has inten-
sively investigated the physiological processes regulating both
body weight and energy metabolism. Interestingly, analysis of
the nutritional disorders associated with overweight and
obesity reveals prominent prolonged periods of positive
energy balance that are especially associated with high-fat
diet ingestion in our Western countries. It has become clear
that obesity and type 2 diabetes are characterized by a low
grade inﬂammatory tone associated with the development of
insulin resistance [1]. Importantly, one of the major ques-
tions that remains of utmost importance is why and how
metabolic diseases are so commonly linked to inﬂammatory
processes.
Among the causes involved in the development of low
grade inﬂammation and metabolic disorders on obesity, we
and others have recently proposed that the gut microbiota
could be considered as one environmental factor impacting
on adipose tissue development, glucose homeostasis and low
grade inﬂammation. Knowing that the gut microbiota consists
of as many as 100 trillion microorganisms, it is conceivable
that host–bacterial mutualism leads to the control of numer-
ous physiological functions [2–4].
Low grade inﬂammation: hidden behind
the shadow of the gut microbiota?
Numerous data showing the role of the gut microbiota in
the extraction of energy from the diet and the development
of obesity and related metabolic disorders are convincing
[5,6]; however, this theory does not help to unravel the
interplay between obesity-related metabolic disorders and
the development of a low grade inﬂammation.
Recently, we have demonstrated that a speciﬁc compound
derived from the gut microbiota could act as a triggering
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factor in the development of insulin resistance, type 2 diabe-
tes and inﬂammation [7–9]. Brieﬂy, we identiﬁed the lipo-
polysaccharide (LPS) from Gram-negative bacteria as one of
the triggering factors in the early development of metabolic
diseases and the cascade of inﬂammation [7]. We demon-
strated that excess dietary lipid intake not only increases
systemic exposure to potentially pro-inﬂammatory free fatty
acids and their derivatives, but more speciﬁcally facilitates
the absorption of endotoxins, leading to a higher plasma LPS
level. This novel concept was deﬁned as ‘metabolic endotox-
aemia’ [7]. It worth mentioning that this metabolic endotox-
aemia is based on endotoxin activity measurement and
thereby can account for several lipopolysaccharides (coming
from different Gram-negative bacteria). Among the mecha-
nisms involved in the development of metabolic endotoxa-
emia on high-fat diet induced obesity, we identiﬁed the key
role of the gut barrier. The role of the gut epithelium under
healthy physiological conditions is mainly to act as a powerful
and continuous barrier that prevents bacterial translocation
(i.e. whole bacterial cells, LPS, or any other bacteria-derived
compounds). However, various situations (stress, alcohol
consumption, fat intake) have been described to alter this
protective function leading to a leaky gut (and thereby pro-
moting metabolic endotoxaemia) [9–13].
Metabolic endotoxaemia and gut barrier
function: novel insight into the gut
microbiota?
We and others have suggested that changes in the distribu-
tion and localization of two tight junction proteins (zonula
occludens-1 and occludin) in the intestinal tissue are associ-
ated with higher gut permeability in obese and diabetic
rodents. This phenomenon has been directly linked to spe-
ciﬁc changes in the gut microbiome [9–13]. In addition, we
have demonstrated that speciﬁc changes of the gut microbi-
ota by using prebiotics (short chain inulin-type fructans, oli-
gofructose) positively affect the gut barrier function, with a
marked improvement of the gut permeability and the hepatic
and systemic inﬂammatory tone. These interesting effects
observed after changing the gut microbiota by prebiotics
demonstrated a novel microbiota–host interaction dependent
effect. Importantly, we have recently discovered that in addi-
tion to the previously considered impact of prebiotics on Biﬁ-
dobacterium spp. and Lactobacillus spp., prebiotic treatment
modiﬁes up to 102 gut bacterial taxa from the phylum level
down to the 100%-ID phylotype level. Among these, 16 dis-
played a greater than tenfold change in abundance; more
importantly we identiﬁed that Akkermansia muciniphila was
increased by about 80-fold [14]. It is worth mentioning that
this bacterium has been associated with healthy mucosa,
compared with that of patients with inﬂammatory bowel dis-
eases, but also inversely correlated with body weight and
increased after surgical weight-loss procedure, Roux-en-Y
gastric bypass [14].
Interaction between gut microbiota and
enteroendocrine function
Several lines of evidence obtained in our laboratory suggest
that prebiotic treatment not only profoundly affects the gut
microbiota composition but also promotes the production of
glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2
(GLP-2) by increasing the differentiation of stem cells into
enteroendocrine L-cells [10,14]. In addition we found that
the abundance of 25 taxa was correlated (positively or nega-
tively) with the L-cell number; among these Akkermansia mu-
ciniphila was strongly and positively correlated with the L-cell
number (r = 0.72, p 0.01) [14].
Among the mechanisms linking the gut microbiota with
the gut barrier function, we found that prebiotic treatment
signiﬁcantly increases intestinal GLP-2 production (a speciﬁc
gut peptide involved in the control of epithelial cell prolifera-
tion and gut barrier integrity). Interestingly, this phenomenon
was associated with improved tight junction protein distribu-
tion and reduced gut permeability in obese and diabetic mice
[10]. To further examine the key role of GLP-2 in these pro-
tective effects of prebiotics, we blocked the GLP-2 receptors
concomitantly with prebiotic. We found that blocking the
GLP-2 receptor signalling completely abolished the major
features of the prebiotic treatment. Hence, without a func-
tional GLP-2 receptor, the prebiotic treatment failed to
reduce metabolic endotoxaemia, hepatic inﬂammation and
oxidative stress markers [10].
While the relevance of these observations is important,
the mechanisms linking the gut microbiota to the develop-
ment of gut permeability or to the expansion of adipose tis-
sue upon obesity remain elusive. Thus, we have been seeking
for additional mechanisms involved in gut barrier alteration
and adipogenesis.
Interaction between gut microbiota and
the endocannabinoid system
In a recent report, we identiﬁed that the endocannabinoid
(eCB) system could be endowed with this speciﬁc role. The
eCB system is an intercellular system that has attracted the
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attention of the scientiﬁc community because of the interest
in terms of therapeutic targets. Among the main reasons for
investigation of this very speciﬁc system, we can mention
that obesity is associated with greater eCB system tone
(altered expression of cannabinoid receptor 1 (CB1 mRNA),
higher plasma eCB levels or increased adipose tissue eCB
content) [11,15]; that LPS is a potent stimulator of eCB syn-
thesis [11]; and that the blockade to the CB1 receptor
(genetic or pharmacological) protects against obesity, steato-
sis and low grade inﬂammation via unresolved mechanisms.
Given that obesity, inﬂammation and the eCB system are
interconnected, we investigated whether the gut microbiota
and the gut barrier function might be related through modu-
lation of the eCB system. By using (i) axenic vs conventional
mice, (ii) dietary treatments that drastically or selectively
change the composition of the gut microbiota (prebiotics or
antibiotics), or (iii) genetic disruption of gut bacteria–host
interactions (Myd88 knockout mice), or (iv) genetic obese
and diabetic mice, we found that with obesity the gut micro-
biota control the eCB system activity in the colon and in adi-
pose tissue [11,15]. In obese mice (diet-induced or
genetically induced obesity), the eCB system is overactivated
in the intestine and in adipose tissue (Fig. 1). Importantly, we
discovered, both in vivo and in vitro, that the eCB system con-
trols gut barrier function via a CB1 dependent mechanism.
For instance, we found that the pharmacological blockade of
the CB1 receptor in obese mice improves the gut barrier
and reduces metabolic endotoxaemia, by a mechanism inde-
pendent of food intake behaviour. Thus, this was the ﬁrst
report showing that CB1 receptors control gut permeability
through interactions with the gut microbiota [11]. Finally, we
found that the gut microbiota ‘interacts’ with adipose tissue
development and metabolism through eCB–gut microbiota
crosstalk [11] (Fig. 1). Interestingly, we found that prebiotic
treatment normalized the eCB system tone in both the gut
and adipose tissue. These observations have been found in
genetic obese ob/ob mice [11] and in high-fat diet induced
obesity (Cani PD, unpublished data). Among the potential
mechanisms, we have also identiﬁed that endogenous pro-
duction and content of N-arachidonoylethanolamine was
increased in obese animals (colon and both visceral and sub-
cutaneous adipose tissue) [11,15], whereas prebiotic treat-
ment abolished this effect [11] (Cani PD, unpublished data).
N-arachidonoylethanolamine content is directly controlled
via the balance between synthesis and degradation through
N-acylphosphatidylethanolamine phospholipase-D (NAPE-
PLD) and the fatty acid amide hydrolase (FAAH), respec-
tively. In the intestine as well as in adipose tissue, we found
that modulation of the gut microbiota (high-fat diet or prebi-
otics) profoundly affects this pathway, where high-fat diet
feeding increased NAPE-PLD and decreased FAAH mRNA
expression, whereas prebiotics blunted these effects (Cani
PD, unpublished data). Thus, the role of the eCB system in
the control of gut permeability, metabolic endotoxaemia and
fat mass development is becoming clear; however, the mech-
anisms by which the gut microbiota participate in this regula-
tion remain to be fully understood. The direct involvement
of speciﬁc gut microbes and/or of microbial metabolites is
under investigation.
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FIG. 1. The gut microbiota and the endocannabinoid system: impact
of prebiotic-induced changes in the gut microbiota. (a) Obesity
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